For the first time, American researchers have shown that sperm production can be stopped and fully restarted in male mice — without hormones, without permanent effects, and without harming offspring. The breakthrough, published in April 2026 C.E. in the Proceedings of the National Academy of Sciences, brings a long-sought goal in reproductive medicine meaningfully closer to reality.
At a glance
- Reversible male contraception: Cornell scientists used a small molecule called JQ1 to halt sperm production in male mice for three weeks, then stopped treatment — and within six weeks, normal sperm production returned completely.
- Nonhormonal approach: Unlike most contraceptive research, this method targets meiosis directly in the testis, leaving libido and secondary sex characteristics entirely unaffected.
- Healthy offspring: Mice that recovered fertility after treatment bred successfully, and their pups were also fertile — confirming no heritable damage from the intervention.
Why this matters
Right now, men have two main contraceptive options: condoms or vasectomy. Vasectomies are technically reversible through surgery, but the procedure is complex and success rates drop over time. No long-acting, fully reversible, nonhormonal option exists for men.
That gap carries real consequences. The global contraceptive burden falls disproportionately on women, many of whom face hormonal side effects ranging from mood changes to cardiovascular risk. Researchers have long hesitated to develop a male hormonal contraceptive for the same reasons. A safe, nonhormonal male option would shift that balance.
“We were really motivated to look for nonhormonal contraceptive targets in the testis,” said Paula Cohen, professor of genetics at Cornell’s College of Veterinary Medicine and director of the Cornell Reproductive Sciences Center. “Something that stops sperm production without affecting male libido and secondary sex characteristics.”
How the science works
Sperm production runs through three main stages. It begins with stem cells that replenish throughout a man’s life. Those cells then enter meiosis — the division process that halves the chromosome count to produce sex cells. After meiosis, a final stage called spermiogenesis shapes those cells into swimming sperm.
Cohen’s team targeted meiosis deliberately. Disrupting the stem cells would cause permanent infertility. Targeting spermiogenesis too late risked viable sperm surviving and escaping. The middle stage — meiosis, and specifically a phase called prophase 1 — turned out to be the right window.
The researchers used JQ1, a molecule originally developed to study cancer and inflammatory disease. It was never viable as a therapeutic drug because of neurological side effects, but it reliably disrupts prophase 1. That made it a precise research tool to prove the concept. After three weeks of JQ1 treatment, the mice produced no sperm at all. After treatment stopped, healthy sperm production resumed within six weeks. The mice then fathered fertile offspring with no abnormalities.
“Our study shows that mostly we recover normal meiosis and complete sperm function, and more importantly, that the offspring are completely normal,” Cohen said.
What comes next
JQ1 itself is not the end product — its neurological side effects rule that out. But it proved the principle. The team is now testing three new gene targets that, when disrupted, eliminate sperm production entirely in mice with no apparent health effects. The next step is confirming those targets can be switched on and off reversibly.
Cohen and her colleagues plan to launch a company within two years to advance the work toward human trials. If successful, the likely delivery format would be an injection every three months, or possibly a patch — designed to ensure consistent effectiveness. The Gates Foundation supported the research.
The study is co-first-authored by Stephanie Tanis and Leah Simon, both Ph.D. graduates from Cornell’s class of 2025, now postdoctoral researchers at the University of Colorado. Co-authors also include Jelena Lujic and Charles Danko from Cornell’s College of Veterinary Medicine.
It is worth being clear about where the science stands: this is a mouse study. The road from mice to a proven, approved human contraceptive is long, and many promising compounds fail to translate across species. Real-world efficacy, safety in humans, and delivery logistics all remain open questions.
Still, six years of careful work has produced something the field has never had before: a clear proof that meiosis in the testis can be targeted safely, stopped completely, and reversed without lasting harm. That is not a small thing. It is the foundation everything else gets built on.
Read more
For more on this story, see: Cornell University News
For more from Good News for Humankind, see:
- Renewables now make up at least 49% of global power capacity
- U.K. cancer death rates down to their lowest level on record
- The Good News for Humankind archive on global health
About this article
- 🤖 This article is AI-generated, based on a framework created by Peter Schulte.
- 🌍 It aims to be inspirational but clear-eyed, accurate, and evidence-based, and grounded in care for the Earth, peace and belonging for all, and human evolution.
- 💬 Leave your notes and suggestions in the comments below — I will do my best to review and implement where appropriate.
- ✉️ One verified piece of good news, one insight from Antihero Project, every weekday morning. Subscribe free.
More Good News
-
Nearly 20 million measles deaths averted in Africa since 2000
Measles vaccines in Africa have prevented an estimated 19.5 million deaths since 2000 — roughly 800,000 lives saved every year for nearly a quarter century. A new WHO and Gavi analysis credits steady investment in cold-chain systems, community health workers, and political will, with coverage for the critical second measles dose climbing more than tenfold over that stretch. This year, Cabo Verde, Mauritius, and Seychelles became the first sub-Saharan nations to officially eliminate measles and rubella, a milestone once considered out of reach. The story is a powerful reminder that global health progress, though uneven, compounds quietly over decades —…
-
Romania finally recognizes trans man’s identity in landmark E.U. victory
Romanian trans rights took a real leap forward this week, as courts finally ordered the government to legally recognize Arian Mirzarafie-Ahi as male — a recognition the U.K. granted him back in 2020. For years, he lived with two identities depending on which border he crossed, until his case climbed all the way to the E.U.’s top court and came home with a binding answer. That ruling now obligates every E.U. member state to honor gender recognition documents issued by another. It’s a quiet but powerful shift: transgender people across Europe gain stronger footing not through new laws, but through…
-
Alaska judge permanently shields Tongass old-growth forests from logging
The Tongass National Forest just won a major day in court, with a federal judge ruling in March 2026 that the U.S. Forest Service is not legally required to ramp up logging to meet timber industry demand. The decision protects the world’s largest temperate old-growth rainforest — home to roughly a third of what remains of this ecosystem globally, along with wild salmon runs, brown bears, and trees older than 800 years. Tribal nations, fishing crews, and tourism operators stood alongside federal defenders in the case, a reminder that the forest’s value reaches far beyond timber. Wins like this give…
